Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,512.38 -3.89 -0.03%
TOPIX 1,171.40 -1.97 -0.17%
HANG SENG 22,760.24 64.23 0.28%

Apricus Biosciences Receives National Phase Approvals for Vitaros(R) in Ireland and the Netherlands



Apricus Biosciences Receives National Phase Approvals for Vitaros(R) in
Ireland and the Netherlands

SAN DIEGO, Aug. 15, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
("Apricus Bio" or the "Company") (Nasdaq:APRI) (www.apricusbio.com), today
announced that the Irish Medicines Board and the Netherlands' Medicines
Evaluations Board have each granted national phase approvals to Vitaros^®,
indicated for the treatment of patients with erectile dysfunction ("ED"). The
Company has now received a total of four national phase approvals for
Vitaros^® including Ireland, the Netherlands, Sweden and the United Kingdom
("UK").

In June 2013, Apricus Bio announced that its marketing application for
Vitaros^® was approved through the European Decentralized Procedure
("DCP"). Under the DCP, Apricus Bio filed its application for marketing
approval designating Netherlands as the Reference Member State ("RMS") on
behalf of nine other European Concerned Member States ("CMS") participating in
the procedure. The Company continues to work independently, as well as with
its commercialization partners, to obtain country-by-country national phase
approvals in the remaining CMS territories including France, Germany, Italy,
Spain, Belgium and Luxembourg. Once the national phase approvals are secured
on a country-by-country basis, marketing of Vitaros^® can then be initiated in
each country by Apricus Bio's commercialization partners.

"Vitaros^® has now received national approvals in four of the ten European
countries where marketing authorization applications are being pursued," said
Richard Pascoe, Chief Executive Officer of Apricus Bio. "We believe that
Vitaros^® is on track to obtain the remaining European approvals beginning in
the third quarter of this year and continuing through the first quarter of
2014. Our regulatory efforts, along with the actions taken by our existing
European partners, Takeda, Sandoz and Bracco, continue to move successfully
toward making Vitaros^® ready to launch in each of the included territories
across Europe."

Vitaros^® is currently partnered in key markets, including with Takeda in the
UK, Sandoz in Germany, Bracco in Italy and Abbott in Canada. Apricus Bio
recently launched a comprehensive partnering process with the goal of
licensing Vitaros^® in the remaining un-partnered territories in Europe, Latin
America and North Africa. The Company is reviewing bids recently received from
multiple interested parties for the available territories and Company expects
the Vitaros^® partnering process to be completed in the fourth quarter of
2013.

Once launched, Vitaros^® will become the first new and novel erectile
dysfunction product in nearly a decade, and with its unique product profile
that addresses a large number of patients who cannot or do not respond well to
these existing therapies, or who are intolerant to the systematic effects of
PDE5 inhibitors, it is well-positioned for commercial success. In Europe
alone, the existing erectile dysfunction products generated over $1 billion in
sales in 2012. Apricus Bio believes that a significant portion of the market
remains untreated or under-treated, which represents a substantial commercial
opportunity for Vitaros^®.

About Vitaros^®

Vitaros^® has been approved for the treatment of Erectile Dysfunction ("ED")
by the European Health Authorities and by Health Canada. Vitaros^® is a
topically-applied cream formulation of alprostadil, a vasodilator, combined
with our proprietary permeation enhancer DDAIP.HCL, which directly increases
blood flow to the penis, causing an erection. Alprostadil is a widely accepted
alternative to the PDE-5 inhibitors for difficult to treat patients, and
Vitaros^®, which was determined to be safe and effective by the European
Health Authorities and previously by Health Canada, offers greater market
opportunity due to its patient-friendly form versus other alprostadil dosage
forms and also relative to oral ED products. With nearly 150 million men
worldwide who suffer from erectile dysfunction and an ED market size of
approximately $1 billion in revenue in Europe alone, Vitaros^® represents a
major market opportunity for Apricus Bio and its commercial partners given its
unique product profile and its potential to treat a large underserved
population.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a pharmaceutical company that develops and
markets innovative treatments that help large patient populations across
numerous, large-market therapeutic classes including male and female sexual
health. The Company has one approved product, Vitaros^®, for the treatment of
erectile dysfunction, which is now approved in Europe and Canada and will be
commercialized by Apricus Bio's marketing partners, which include Abbott
Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG
(Sandoz), and Bracco SpA.  Femprox^®, the Company's product candidate for the
treatment of female sexual arousal disorder, has successfully completed a
nearly 400-subject proof-of-concept study.

For further information on Apricus Bio, visit http://www.apricusbio.com.

Apricus Bio's Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended:
with the exception of the historical information contained in this release,
the matters described herein contain forward-looking statements that involve
risks and uncertainties that may individually or mutually impact the matters
herein described for a variety of reasons that are outside the control of the
Company, including, but not limited to, its ability to further develop its
product Vitaros^® for erectile dysfunction, and product candidate Femprox^®
for Female Sexual Interest and Arousal Disorder among others; to have its
product and product candidates receive additional patent protection and be
approved by relevant regulatory authorities in Europe, the United States,
Canada and in other countries, such as additional national phase approvals for
Vitaros^® in the remaining CMS territories; to successfully commercialize such
product and product candidates and other NexACT^® product candidates and drug
delivery technology; to have its French subsidiaries reorganize or liquidate
successfully; and to achieve its other development, commercialization and
financial goals. Readers are cautioned not to place undue reliance on these
forward-looking statements as actual results could differ materially from the
forward-looking statements contained herein. Readers are urged to read the
risk factors set forth in the Company's most recent annual report on Form
10-K, subsequent quarterly reports filed on Form 10-Q and other filings made
with the SEC. Copies of these reports are available from the SEC's website or
without charge from the Company.

CONTACT: Apricus Bio Investor Relations:
        
         David Pitts or Lourdes Catala
         Argot Partners
         212-600-1902
         david@argotpartners.com
         lourdes@argotpartners.com

Apricus logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement